系统性硬化症的抗凝固疗法是否需要重新考虑?
Francesco Marongiu1, Maria Filomena Ruberto1, Doris Barcellona1
1Department of Medical Sciences and Public Health, Hemostasis and Thrombosis Unit, University of Cagliari and AOU of Cagliari, Cagliari, Italy.
Journal of scleroderma and related disorders
|June 24, 2024
概括
系统性硬化症患者由于血管问题而面临高死亡率. 针对XI因子的新型抗凝剂显示出更安全治疗的希望,临床试验正在进行中.
科学领域:
- 类风湿病学 类风湿病学
- 血液学 血液学 血液学
- 血管生物学 血管生物学
背景情况:
- 系统性硬化是一种罕见的多系统结合组织疾病,其特征是内皮功能障碍,纤维化和血管病变.
- 系统性硬化症中的内皮损伤触发了血小板激活,免疫细胞粘附,并通过产生血栓激素产生了前血栓状态.
- 并发症包括静脉血栓栓塞和肺高血压,当前的抗凝固药物如华法林显示效果不一致.
研究的目的:
- 审查系统性硬化症中血栓形成的病理生理学.
- 讨论当前抗凝药疗法的局限性.
- 引入针对XI因子的新型抗凝策略,以提高安全性和有效性.
主要方法:
- 系统性硬化症病理生理学和血栓形成的文献综述.
- 对系统性硬化症抗凝剂现有临床试验数据的分析.
- 新兴抗XI因子药物开发的概述.
主要成果:
- 系统性硬化症与显著的血栓前活性和血管并发症有关.
- 华法林在这些患者的血栓塞栓症管理中显示出不一致的结果.
- 阿皮克萨班的疗效正在调查中,随机试验的结果正在等待.
结论:
- 新型抗凝血策略,特别是针对XI因子的抗凝血策略,代表了系统性硬化症的有前途的治疗途径.
- 开发最佳的抗凝剂,降低出血风险至关重要.
- 患有全身性硬化症的患者可能是评估这些新药物的正在进行的临床试验的合适候选人.
更多相关视频
08:05Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
4.0K
07:08Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
Published on: September 5, 2017
8.3K
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
